The CurQD® Protocol began in 2011 with the initial clinical trial led by Professor Shomron Ben-Horin, head of the Gastroenterology Department at Sheba Hospital, and Nir Salomon, integrative medical expert.
The four-year, double-blind, placebo-controlled trial tested the efficacy of one of the first compounds within CurQD® (gut-directed curcumin) for ulcerative colitis. Many of the participants, all failing conventional treatment at the onset of the trial, achieved clinical and endoscopic remission within 4 weeks. The trial was published in 2015 in Clinical Gastroenterology and Hepatology.
From 2015 to 2019, Ben-Horin and Salomon gathered clinical experience with thousands of difficult-to-treat patients referred from the top 5 medical centers in Israel. During this time they researched and developed unique formulations of herbal extracts to address refractory and severe IBD who were not responding to medical treatments.
The data was analyzed in a 2022 retrospective study, as presented at the United European Gastroenterology conference in Vienna. The study showed that after 8-12 weeks on CurQD® 78% of patients achieved clinical response & remission.
In 2021, CurQD® was licensed by Sheba Medical Center. Salomon and Ben-Horin went on to found Evinature to continue their research and promote safe, clinically proven natural therapies to patients around the world.
Prof. Shomron Ben-Horin M.D.
Co-founder of Evinature. Co-founder & Clinical Expert. Chief of the Gastroenterology Department & Director of the Gastro-Immunology Research Laboratory at Sheba Medical Center, one of Newsweek’s 10 best hospitals in the world.
Currently a professor of Medicine at Tel Aviv University, Ben-Horin has been the President of the Israel IBD Society, a member of the Scientific Committee of the European Crohn’s & Colitis Organization (ECCO), and an Associate Editor of the Journal of Crohn & Colitis. He is currently a member of the prestigious International Organization of IBD (IOIBD), and a member of the Editorial Board of leading journals, Gut, JCC and APT.
Ben-Horin has been invited to lecture at numerous IBD congresses and research meetings around the world, and serves as a consultant to several biotech and biopharma companies and was involved in the initiation of the CONFER project by the European Crohn’s & Colitis Organization. He is also the Director of IBD Passport, a web-based global support program for traveling IBD patients.
Nir Salomon
Co-founder of Evinature. Co-founder & Integrative Gastroenterology Specialist. Founder & Director of the Integrative Gastroenterology unit at Sheba Medical Center & co-founder and acting CEO of the Sino-Israeli Research Foundation (SIRF).
Nir Salomon has led innovative research projects, earning several prestigious awards for “breakthrough innovation” and “clinical merit” in his work. He has been invited to lecture around the world, advocating integrative methods at both conventional and alternative medical conferences.
Nir’s background in TCM recently led to an investigation of CurQD® as a therapy for various gastro disorders. Despite a long history of traditional use, the compounds had yet to be scrutinized under the scientific lens. In 2011, Nir teamed up with Professor Ben-Horin to lead a four-year international placebo-controlled trial testing an innovative natural formulation for UC patients. The results sparked the founding of Evinature, led to a retrospective study on the data of thousands of patients taking CurQD®, and the first clinical trial on the complete CurQD® formulation (soon to be published).
